Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Medical therapy with tranexamic acid in autosomal dominant polycystic kidney disease patients with severe haematuria.

Peces R, Aguilar A, Vega C, Cuesta E, Peces C, Selgas R.

Nefrologia. 2012;32(2):160-5. doi: 10.3265/Nefrologia.pre2011.Dec.11210. Epub 2012 Feb 4. English, Spanish.

2.
3.

[Co-inheritance of autosomal dominant polycystic kidney disease and sickle cell trait in African Americans].

Peces R, Peces C, Cuesta-López E, Vega-Cabrera C, Azorín S, Pérez-Dueñas V, Selgas R.

Nefrologia. 2011;31(2):162-8. doi: 10.3265/Nefrologia.pre2010.Dec.10660. Spanish.

4.

Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: tranexamic acid in life-threatening haematuria.

[No authors listed]

Emerg Med J. 2015 Feb;32(2):168-9. doi: 10.1136/emermed-2014-204573.1. Review.

PMID:
25605262
5.

Treatment of Persistent Gross Hematuria with Tranexamic Acid in Autosomal Dominant Polycystic Kidney Disease.

Yao Q, Wu M, Zhou J, Zhou M, Chen D, Fu L, Bian R, Xing X, Sun L, Hu X, Li L, Dai B, Wüthrich RP, Ma Y, Mei CL.

Kidney Blood Press Res. 2017;42(1):156-164. doi: 10.1159/000474961. Epub 2017 Apr 11.

6.

Tranexamic acid and thrombosis.

[No authors listed]

Prescrire Int. 2013 Jul;22(140):182-3.

PMID:
23951593
7.

Complications of autosomal dominant polycystic kidney disease in 50 haemodialysed patients. A case-control study. The U.C.L. Collaborative Group.

Christophe JL, van Ypersele de Strihou C, Pirson Y.

Nephrol Dial Transplant. 1996 Jul;11(7):1271-6.

PMID:
8672022
8.

Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study.

McGovern AP, Jones S, van Vlymen J, Saggar AK, Sandford R, de Lusignan S.

BMC Nephrol. 2014 Nov 20;15:182. doi: 10.1186/1471-2369-15-182.

9.

Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease.

Gabow PA, Duley I, Johnson AM.

Am J Kidney Dis. 1992 Aug;20(2):140-3.

PMID:
1496966
10.

Positron emission tomography in the diagnostic pathway for intracystic infection in adpkd and "cystic" kidneys. a case series.

Piccoli GB, Arena V, Consiglio V, Deagostini MC, Pelosi E, Douroukas A, Penna D, Cortese G.

BMC Nephrol. 2011 Sep 29;12:48. doi: 10.1186/1471-2369-12-48.

11.

Native nephrectomy for autosomal dominant polycystic kidney disease: before or after kidney transplantation?

Kirkman MA, van Dellen D, Mehra S, Campbell BA, Tavakoli A, Pararajasingam R, Parrott NR, Riad HN, McWilliam L, Augustine T.

BJU Int. 2011 Aug;108(4):590-4. doi: 10.1111/j.1464-410X.2010.09938.x. Epub 2010 Dec 16.

12.

Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.

Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS.

Am J Kidney Dis. 2011 May;57(5):692-9. doi: 10.1053/j.ajkd.2010.11.029. Epub 2011 Feb 17.

PMID:
21333426
13.

Experience with autosomal dominant polycystic kidney disease in patients before and after renal transplantation: a 7-year observation.

Sulikowski T, Tejchman K, Zietek Z, Rózański J, Domański L, Kamiński M, Sieńko J, Romanowski M, Nowacki M, Pabisiak K, Kaczmarczyk M, Ciechanowski K, Ciechanowicz A, Ostrowski M.

Transplant Proc. 2009 Jan-Feb;41(1):177-80. doi: 10.1016/j.transproceed.2008.10.034.

PMID:
19249508
14.

Treatment of bleeding upper aerodigestive tract tumor-a novel approach with antifibrinolytic agent: case series and literature review.

Low TH, Huang J, Reid C, Elliott M, Clark JR.

Laryngoscope. 2013 Oct;123(10):2449-52. doi: 10.1002/lary.24064. Epub 2013 Apr 1. Review.

PMID:
23553514
15.

Laparoscopic nephrectomy in patients with end-stage renal disease and autosomal dominant polycystic kidney disease.

Dunn MD, Portis AJ, Elbahnasy AM, Shalhav AL, Rothstein M, McDougall EM, Clayman RV.

Am J Kidney Dis. 2000 Apr;35(4):720-5.

PMID:
10739795
16.

Native nephrectomy in transplant patients with autosomal dominant polycystic kidney disease.

Patel P, Horsfield C, Compton F, Taylor J, Koffman G, Olsburgh J.

Ann R Coll Surg Engl. 2011 Jul;93(5):391-5. doi: 10.1308/003588411X582690.

17.

Oral tranexamic acid as a novel treatment option for persistent haematuria in patients with sickle cell disease.

Davis NF, McGuire BB, Lawlor L, O'Gorman P, O'Malley KJ, Fitzpatrick JM.

Ann Hematol. 2010 Nov;89(11):1179-80. doi: 10.1007/s00277-010-0936-y. Epub 2010 Apr 1. No abstract available.

PMID:
20358201
18.

Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.

Stallone G, Infante B, Grandaliano G, Bristogiannis C, Macarini L, Mezzopane D, Bruno F, Montemurno E, Schirinzi A, Sabbatini M, Pisani A, Tataranni T, Schena FP, Gesualdo L.

Nephrol Dial Transplant. 2012 Sep;27(9):3560-7. doi: 10.1093/ndt/gfs264. Epub 2012 Jul 10.

PMID:
22785114
19.

Tranexamic acid is beneficial as adjunctive therapy in treating major upper gastrointestinal bleeding in dialysis patients.

Sabovic M, Lavre J, Vujkovac B.

Nephrol Dial Transplant. 2003 Jul;18(7):1388-91.

PMID:
12808178
20.

Tranexamic Acid treatment of life-threatening hematuria in polycystic kidney disease.

Alameel T, West M.

Int J Nephrol. 2011;2011:203579. doi: 10.4061/2011/203579. Epub 2011 Jun 1.

Supplemental Content

Support Center